Latest News-SENHWA BIOSCIENCES, INC. Mediaroom_Page

Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC "Blockbuster" Therapy

TAIPEI and SAN DIEGO, Dec. 28, 2025 /PRNewswire/ -- Following its recent clinical collaboration wit...

2025-12-29 10:24 2529

Senhwa Biosciences Highlights AI-Validated Oncology Platform and Strategic Clinical Collaborations Targeting Next-Generation Immuno-Oncology products at Its 2025 Annual Investor Conference

TAIPEI and SAN DIEGO, Dec. 23, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinic...

2025-12-23 20:00 2696

Google AI Breakthrough Highlights Silmitasertib (CX-4945) as a Novel Pathway in Cancer Immunotherapy

TAIPEI and SAN DIEGO, Oct. 20, 2025 /PRNewswire/ -- Senhwa Biosciences's investigational new drug S...

2025-10-21 10:49 1194

Senhwa Biosciences CX-5461 Secures NCI Support to Advance into MYC-Driven Lymphoma, Driving Cross-Cancer and Global Licensing Value

TAIPEI and SAN DIEGO, Sept. 5, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinic...

2025-09-05 16:46 1552

US NCI Sponsors Senhwa Biosciences' Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma

TAIPEI and SAN DIEGO, Aug. 7, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new dru...

2025-08-07 14:35 1793

Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors

TAIPEI and SAN DIEGO, July 15, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new dr...

2025-07-16 10:32 2147

Senhwa Biosciences Highlights Breakthroughs in Dual First-in-Class Drug Programs at Annual Shareholders' Meeting Today

TAIPEI and SAN DIEGO, June 25, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinic...

2025-06-25 19:00 2320

Senhwa Biosciences Announces Positive Clinical Data from Phase 1/Expansion Trial of Silmitasertib (CX-4945) in the Treatment of Basal Cell Carcinoma

Basal Cell Carcinoma CSR Highlights * CX-4945 Monotherapy: Progression-free survival (PFS) excee...

2025-04-02 15:56 2675

Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director

TAIPEI and SAN DIEGO, Nov. 1, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug de...

2024-11-01 15:28 2588

US FDA issues Study May Proceed letter for the Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors, Sponsored by the US National Cancer Institute

TAIPEI and SAN DIEGO, Oct. 14, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug d...

2024-10-14 19:00 2705

Senhwa Biosciences Announces IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors sponsored by NCI

TAIPEI and SAN DIEGO, Sept. 17, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), , a dru...

2024-09-18 10:06 2639

US FDA Grants RPD Designation to Senhwa Biosciences Silmitasertib for Pediatric Neuroblastoma

TAIPEI and SAN DIEGO, Sept. 13, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new d...

2024-09-13 13:49 1796

Senhwa Biosciences Presents Clinical Data Abstract on Pidnarulex at 2024 ESMO Congress

* The study involved end-stage oncology patients with no other suitable treatment options. * In...

2024-09-09 10:33 2046

Senhwa Biosciences receives US FDA Study May Proceed letter for the Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors

TAIPEI and SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug de...

2024-08-07 08:49 2960

Senhwa Biosciences Clinical Data Abstract of Pidnarulex Accepted for Presentation at 2024 ESMO Congress

TAIPEI and SAN DIEGO, July 12, 2024 /PRNewswire/ -- Senhwa Biosciences' new drug Pidnarulex (CX-546...

2024-07-12 19:00 5257

Senhwa Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer

TAIPEI and SAN DIEGO, Oct. 31, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug d...

2022-10-31 19:00 3021

Senhwa's Pindnarulex in Combination Study with Pfizer's Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC

TAIPEI and SAN DIEGO, June 6, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug de...

2022-06-06 21:00 2729

At the 2022 AAD Annual Meeting, Senhwa Presents Positive Initial Data from Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma

* Early results showed 2 laBCC (locally advanced Basal Cell Carcinoma) subjects out of 10 experie...

2022-03-28 19:00 2109

Senhwa's Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations

TAIPEI and SAN DIEGO, Jan. 25, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug d...

2022-01-25 20:00 2514

Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer

TAIPEI and SAN DIEGO, Jan. 20, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug d...

2022-01-20 20:00 2601